Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
The pooled prevalence of GERD in the Indian population is 15.6 %
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
The 200 bedded hospital owned & operated by Alexis
Subscribe To Our Newsletter & Stay Updated
